Work with thought leaders and academic experts in hematology

Companies can greatly benefit from collaborating with academic researchers in the field of Hematology. These experts bring a wealth of knowledge and experience that can enhance research, development, and innovation in various ways. Here are some key reasons why companies would want to collaborate with Hematology researchers: 1. Cutting-edge Research: Hematology researchers are at the forefront of scientific advancements in blood disorders and diseases. Collaborating with them can provide access to the latest research findings and breakthroughs. 2. Expertise in Clinical Trials: Hematology researchers have extensive experience in conducting clinical trials for new treatments and therapies. Partnering with them can accelerate the development and testing of new drugs. 3. Access to Specialized Equipment: Hematology researchers often have access to state-of-the-art equipment and facilities. Collaborating with them can provide companies with access to advanced technologies for research and development. 4. Collaboration on Publications: Working with Hematology researchers can lead to joint publications in reputable scientific journals. This can enhance the company's reputation and credibility in the field. 5. Networking Opportunities: Collaborating with Hematology researchers allows companies to expand their professional network and establish connections with other experts in the field. By collaborating with academic researchers in Hematology, companies can tap into a vast pool of knowledge and expertise, leading to improved research outcomes and potential commercial success.

Researchers on NotedSource with backgrounds in hematology include Garrett A. Perchetti, Research Scientist - Virology, Burcu Vitrinel, Ph.D., Elvira Forte, Boris Leibovitch, Ping Luo, Dr. Everson A Nunes, Ph.D., Dushani L. Palliyaguru, Ph.D., John M Baust, Ph.D, Jeffrey Townsend, Khoa Nguyen, Luke Connelly, Thaddeus Allen, and Mohsen Fathzadeh.

Garrett A. Perchetti, Research Scientist - Virology

New York
Research Scientist and MD Candidate in virology with publications on infectious diseases, laboratory medicine, viral genetics, and clinical medicine
Most Relevant Research Expertise
Hematology
Other Research Expertise (14)
Virology
Microbiology
Infectious Diseases
SARS-CoV-2
COVID-19
And 9 more
About
Garrett A. Perchetti is a highly accomplished research scientist in the field of virology. He received a Bachelor of Science in Microbiology and a Bachelor of Arts in Art History from the University of Washington. His interest in both science and the arts led him to pursue a career in virology, where he could combine his passion for understanding the natural world with his creative thinking skills. After completing his undergraduate studies, Garrett continued his education by earning a Medical Degree from Ross University School of Medicine in 2025. During his time in medical school, he developed a keen interest in virology and infectious diseases, which ultimately led him to specialize in this field. Garrett's educational background is complemented by his extensive experience as a research scientist. He has worked at the University of Washington School of Medicine, where he has conducted groundbreaking research on various types of viruses. His work has been published in numerous scientific journals, and he has presented his findings at international conferences. Garrett's contributions to the field of virology have been widely recognized, and he has received several awards and accolades for his work. He is known for his meticulous attention to detail, innovative thinking, and ability to collaborate effectively with other researchers. In his free time, Garrett enjoys painting, hiking, and traveling. He is also passionate about raising awareness about the importance of vaccinations and promoting public health initiatives. With his exceptional education and extensive experience, Garrett A. Perchetti is a valuable asset to the field of virology and will continue to make significant contributions in the future.
Most Relevant Publications (1+)

28 total publications

Cytomegalovirus breakthrough and resistance during letermovir prophylaxis

Bone Marrow Transplantation / Jan 24, 2023

Perchetti, G. A., Biernacki, M. A., Xie, H., Castor, J., Joncas-Schronce, L., Ueda Oshima, M., Kim, Y., Jerome, K. R., Sandmaier, B. M., Martin, P. J., Boeckh, M., Greninger, A. L., & Zamora, D. (2023). Cytomegalovirus breakthrough and resistance during letermovir prophylaxis. Bone Marrow Transplantation, 58(4), 430–436. https://doi.org/10.1038/s41409-023-01920-w

See Full Profile

Elvira Forte

New York, New York, United States of America
Scientific strategist • Senior Scientist • Senior Scientific Editor
Most Relevant Research Expertise
Hematology
Other Research Expertise (26)
fibrosis
inflammation
cardiomyopathies
Physiology
Cardiology and Cardiovascular Medicine
And 21 more
About
Motivated and growth-driven biomedical scientist with over 15 years of experience in the cardiovascular field. Strong background in cell and molecular biology, data analysis, and interpretation. Seeking #newopportunities to deliver value as a Senior Scientist, Associate Principal Scientist, Scientific Liaison, or Scientific Consultant within a company that combines new technologies such as single-cell omics and AI for drug discovery and personalized medicine. <br> Throughout my career, I've used various in vivo and in vitro models to investigate the molecular and cellular mechanisms of fibrosis and inflammation in the heart, and how these mechanisms are affected in mice with different genetic backgrounds. My experience includes project management and mentoring. I completed three projects involving international collaborations, supervised two junior researchers, and taught cellular and molecular techniques to at least six professionals. As one of the launching editors and senior editor at Nature Cardiovascular Research, I oversaw the quality of the content published in the journal and the editorial process. I collaborated with authors, reviewers, and editors to ensure the highest standards of scientific rigor, relevance, and innovation. I also contributed to the journal's vision, strategy, and outreach, promoting the latest advances and discoveries in the cardiovascular and hematology fields. This experience has sharpened my analytical and communication skills and broadened my understanding of the field, covering a wide range of studies, from basic research to clinical, epidemiological, and public health research. My mission is to advance the knowledge and practice of cardiovascular medicine and to bridge the gap between research and clinical applications. Keywords: cardiovascular, #fibrosis, inflammation, cardioimmunology, RNA, single-cell biology, #transcriptomics, imaging, animal models, small animal surgery, and scientific writing.
Most Relevant Publications (2+)

63 total publications

TGFβ-Dependent Epithelial-to-Mesenchymal Transition Is Required to Generate Cardiospheres from Human Adult Heart Biopsies

Stem Cells and Development / Nov 20, 2012

Forte, E., Miraldi, F., Chimenti, I., Angelini, F., Zeuner, A., Giacomello, A., Mercola, M., & Messina, E. (2012). TGFβ-Dependent Epithelial-to-Mesenchymal Transition Is Required to Generate Cardiospheres from Human Adult Heart Biopsies. Stem Cells and Development, 21(17), 3081–3090. https://doi.org/10.1089/scd.2012.0277

New Perspectives to Repair a Broken Heart

Cardiovascular &amp; Hematological Agents in Medicinal Chemistry / Apr 01, 2009

Gaetani, R., Barile, L., Forte, E., Chimenti, I., Ionta, V., Di Consiglio, A., Miraldi, F., Frati, G., Messina, E., & Giacomello, A. (2009). New Perspectives to Repair a Broken Heart. Cardiovascular &amp; Hematological Agents in Medicinal Chemistry, 7(2), 91–107. https://doi.org/10.2174/187152509787847128

See Full Profile

Ping Luo

Toronto, Ontario, Canada
Bioinformatics Specialist at Princess Margaret Cancer Centre with experience in deep learning
Most Relevant Research Expertise
Hematology
Other Research Expertise (21)
single-cell genomics
deep learning
complex network analysis
Genetics (clinical)
Genetics
And 16 more
About
8 years of science and engineering experience integrating multi-omics data to identify biomarkers for cancer studies. Seeking to apply data analytics expertise to develop new diagnosis and treatment strategies.
Most Relevant Publications (1+)

23 total publications

Normalization of the Immune Microenvironment during Lenalidomide Maintenance Is Associated with Sustained MRD Negativity in Patients with Multiple Myeloma

Blood / Nov 05, 2021

Coffey, D. G., Maura, F., Gonzalez-Kozlova, E., Diaz-Mejia3, J., Luo, P., Zhang, Y., Xu, Y., Warren, E. H., Smith, E. L., Cho, H. J., Lesokhin, A., Diamond, B., Kazandjian, D., Pugh, T. J., Green, D. J., Gnjatic, S., & Landgren, O. (2021). Normalization of the Immune Microenvironment during Lenalidomide Maintenance Is Associated with Sustained MRD Negativity in Patients with Multiple Myeloma. Blood, 138(Supplement 1), 329–329. https://doi.org/10.1182/blood-2021-154506

See Full Profile

Dr. Everson A Nunes, Ph.D.

Hamilton, Ontario, Canada
Post-Doctoral Fellow at McMaster University | former Associate Professor - Physiological Sciences
Most Relevant Research Expertise
Hematology
Other Research Expertise (39)
skeletal muscle
nutrition
physical activity
obesity
cancer
And 34 more
About
Dr. Everson A Nunes is a highly accomplished researcher and educator in the field of physiological sciences. He received his Ph.D. in Cellular and Molecular Biology with a focus on Physiological Sciences from Universidade Federal do Paraná in 2009, after completing a BSc in Human Nutrition and an MSc in Physiological Sciences. He also holds a specialization in Exercise Physiology and a BSc in Biological Sciences from Universidade Federal do Paraná. Dr. Nunes has a strong background in research, having completed two post-doctoral fellowships at McMaster University and Universidade Federal do Paraná. He has also held positions as an associate professor and assistant professor at Universidade Federal de Santa Catarina. He has published numerous articles in peer-reviewed journals, and his research focuses on the effects of exercise and nutrition on physiological processes in the human body. In addition to his research, Dr. Nunes is also a dedicated educator. He has taught at various universities in Brazil, including Universidade Federal de Santa Catarina, Universidade Gama Filho, Faculdades Integradas Espírita, Pontificia Universidade Católica do Paraná, and Faculdade do Litoral Sul. He is known for his dynamic teaching style and his ability to engage students in complex physiological concepts. Dr. Nunes is a member of several professional organizations, including the American Society for Nutrition, the Canadian Society of Exercise Physiology, the Canadian Nutrition Society and the Brazilian Society of Physiology. He is also a regular speaker at national and international conferences, sharing his expertise and research findings with colleagues and students. Overall, Dr. Nunes is a highly qualified and experienced professional in physiological sciences, metabolism, cancer and nutrition. His dedication to research and education makes him a valuable asset to any institution.
Most Relevant Publications (1+)

97 total publications

Effects of omega-3 fatty acids on regulatory T cells in hematologic neoplasms

Revista Brasileira de Hematologia e Hemoterapia / Jan 01, 2013

Betiati, D. da S. B., Oliveira, P. F. de, Camargo, C. de Q., Nunes, E. A., & Trindade, E. B. S. de M. (2013). Effects of omega-3 fatty acids on regulatory T cells in hematologic neoplasms. Revista Brasileira de Hematologia e Hemoterapia, 35(2). https://doi.org/10.5581/1516-8484.20130033

See Full Profile

John M Baust, Ph.D

Ithaca, New York, United States of America
Proven success in delivering best-in-class services across scientific, commercial and education environments.
Most Relevant Research Expertise
Hematology
Other Research Expertise (16)
Cell Biology
Biotechnology
Biomedical Engineering
Transplantation
Surgery
And 11 more
About
***Proven success in delivering best-in-class services across highly regulated scientific and commercial environments.*** * Resourceful, dynamic, and future-focused professional; equipped with strategic leadership, business, research, and academic expertise with career excellence in conducting in-depth research, leading multi-faceted R&D projects, and developing new products and treatments. * Dedicated, driven self-starter focused on developing innovative life changing technologies and procedures advancing the areas of cancer treatment, regenerative medicine and cell therapy.   * Substantial experience in providing oversight for medical device development, pre-clinical studies, cancer therapy, stem cell preservation, cell therapy, tissue engineering, and organ transplantation, etc. * Astute at establishing solid relationships with stakeholders and industry leaders to drive innovative ideas and lead collaborative efforts in pursuit of accomplishing long-term milestones. * Successful in delivering interactive academic instruction across higher education settings offering captivating lectures on Biology and Entrepreneurship courses in accordance with the organizational mission. * Accredited with authoring, managing, and executing multi-million dollar grants, corporate contracts * Accomplished author of numerous patents and high profile publications to disseminate essential research findings.
Most Relevant Publications (1+)

68 total publications

Dose Escalation of Vitamin D3 Yields Similar Cryosurgical Outcome to Single Dose Exposure in a Prostate Cancer Model

Cancer Control / Jan 01, 2018

Santucci, K. L., Baust, J. M., Snyder, K. K., Van Buskirk, R. G., & Baust, J. G. (2018). Dose Escalation of Vitamin D3 Yields Similar Cryosurgical Outcome to Single Dose Exposure in a Prostate Cancer Model. Cancer Control, 25(1), 107327481875741. https://doi.org/10.1177/1073274818757418

See Full Profile

Jeffrey Townsend

New Haven, CT
Professor of Biostatistics and Ecology & Evolutionary Biology
Most Relevant Research Expertise
Hematology
Other Research Expertise (52)
Evolutionary Genomics
Microbiology
Infectious Diseases
Genetics
Cell Biology
And 47 more
About
Jeffrey Townsend is a Professor of Organismic and Evolutionary Biology at Yale University. He received his Ph.D. from Harvard University in 2002 and his Sc.B. from Brown University in 1994. He has been a teacher at St. Ann's School and an Assistant Professor at the University of Connecticut. He is currently the Elihu Professor of Biostatistics at Yale University.
Most Relevant Publications (3+)

207 total publications

Not only mutations but also tumorigenesis can be substantially attributed to DNA damage from reactive oxygen species in RUNX1::RUNX1T1-fusion-positive acute myeloid leukemia

Leukemia / Nov 11, 2022

Mandell, J. D., Fisk, J. N., Cyrenne, E., Xu, M. L., Cannataro, V. L., & Townsend, J. P. (2022). Not only mutations but also tumorigenesis can be substantially attributed to DNA damage from reactive oxygen species in RUNX1::RUNX1T1-fusion-positive acute myeloid leukemia. Leukemia, 36(12), 2931–2933. https://doi.org/10.1038/s41375-022-01752-5

Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function

Annals of Oncology / Jan 01, 2017

Choi, M., Kadara, H., Zhang, J., Parra, E. R., Rodriguez-Canales, J., Gaffney, S. G., Zhao, Z., Behrens, C., Fujimoto, J., Chow, C., Kim, K., Kalhor, N., Moran, C., Rimm, D., Swisher, S., Gibbons, D. L., Heymach, J., Kaftan, E., Townsend, J. P., … Wistuba, I. I. (2017). Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function. Annals of Oncology, 28(1), 83–89. https://doi.org/10.1093/annonc/mdw437

Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up

Annals of Oncology / Jan 01, 2017

Kadara, H., Choi, M., Zhang, J., Parra, E. R., Rodriguez-Canales, J., Gaffney, S. G., Zhao, Z., Behrens, C., Fujimoto, J., Chow, C., Yoo, Y., Kalhor, N., Moran, C., Rimm, D., Swisher, S., Gibbons, D. L., Heymach, J., Kaftan, E., Townsend, J. P., … Herbst, R. S. (2017). Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. Annals of Oncology, 28(1), 75–82. https://doi.org/10.1093/annonc/mdw436

See Full Profile

Khoa Nguyen

San Francisco, California, United States of America
Life Sciences Expert with 18-Year Experience in Immunology, Metabolism, Neuroscience, and Biotech Entrepreuneuship
Most Relevant Research Expertise
Hematology
Other Research Expertise (25)
Metabolic Physiology
Neuroimmunology
Oncology
Biochemistry
Molecular Biology
And 20 more
About
Dr. Nguyen is an experienced immunologist who specializes in studies of cellular and molecular mechanisms by which innate immunity and energy metabolic pathways regulate disease development. He has more than 15 years of experience in building innovative preclinical research programs to investigate neurological, metabolic, and inflammatory diseases as well as 7 years of experience in early stage biotechnology R&D (including drug screening, pharmacology and toxicology). His PhD thesis work at the intersection of immunology and metabolism resulted in the discovery of the critical role of innate immunity in the development of metabolic diseases. These findings were highlighted in two seminal publications in Nature and Science and a series of other publications in high profile journals such as Cell, Nature Immunology, Nature Medicine, and Nature Reviews Immunology; and are of great clinical interest with regard to the understanding of the complex pathways that contribute to metabolic syndromes as well as the development of new cures for the treatment of these disorders. In his post-graduate career, Dr. Nguyen applied his technical expertise in cellular immunology and molecular biology; and his knowledge-based strength in innate immunity and metabolism into the field of neurobiology. His pioneering neuro-immunology research program in the last seven years led to the discovery of the role of distinct metabolic pathways in innate immune cells of the brain in the development of neurological diseases. Propelled by these exciting findings was the development of drug candidates to treat neuroinflammation and neurodegeneration, which is currently moving toward clinical development stage for the treatment of Amyotrophic Lateral Sclerosis and Multiple Sclerosis by Tranquis Therapeutics, an early-stage biotechnology company, of which Dr. Nguyen is a scientific founder.
Most Relevant Publications (1+)

47 total publications

Serum amyloid A overrides Treg anergy via monocyte-dependent and Treg-intrinsic, SOCS3-associated pathways

Blood / Apr 07, 2011

Nguyen, K. D., Macaubas, C., Nadeau, K. C., Truong, P., Yoon, T., Lee, T., Park, J. L., & Mellins, E. D. (2011). Serum amyloid A overrides Treg anergy via monocyte-dependent and Treg-intrinsic, SOCS3-associated pathways. Blood, 117(14), 3793–3798. https://doi.org/10.1182/blood-2010-11-318832

See Full Profile

Luke Connelly

Professor of Health Economics, The University of Queensland, CBEH
Most Relevant Research Expertise
Hematology
Other Research Expertise (42)
Health economics
insurance
Public Health, Environmental and Occupational Health
Safety, Risk, Reliability and Quality
Human Factors and Ergonomics
And 37 more
About
Luke Connelly is Professor of Health Economics at the Centre for the Business and Economics of Health. He also holds a Professorial appointment (part-time) at The University of Bologna, to which he was appointed in 2017 via the Italian “Direct Call” ([link](https://www.unibo.it/sitoweb/luke.connelly/en)) process. In 2019 he was appointed as Honorary Professor at The University of Sydney. His main interests are in health economics and insurance economics and the effects of institutions (including legal constructs) on incentives and behaviour. He has also worked in other fields of applied microeconomics, including education economics and transport economics. His publications include papers in *Review of Income and Wealth*, *Health Economics*, *Journal of Health Economics*, *Journal of Risk and Insurance*, *Geneva Papers on Risk and Insurance*, *Accident Analysis and Prevention*, *Journal of Law and Medicine*, *Journal of Clinical Epidemiology*, *European Journal of Health Economics*, *International Journal of Health Economics and Finance*, *Social Science and Medicine*, *Economic Papers*, *Economic Analysis and Policy*, *Journal of Transport Economics and Policy*, *Labour Economics*, *Economics and Human Biology* as well as in a range of clinical journals, including *Lancet*. Luke has served on a number of public committees including the Medical Services Advisory Committee (MSAC), which advises the Australian Minister for Health on the safety, efficacy, effectiveness, and cost-effectiveness of new and extant listings on Australia's Medicare Benefits Schedule. He has extensive service on other public committees and taskforces as well as extensive teaching and consulting engagements with industry. Over his career he has been a chief investigator on research grants and contracts totalling more than $67m. He is a member of the Editorial Boards of European Journal of Health Economics and the International Journal on Environmental Research and Public Health. He is a member of the International Health Economics Association's Arrow Awards Committee, which awards an annual prize in honour of Nobel Laureate Kenneth Arrow for the best paper in the field. He is currently Guest Editor (with Christophe Courbage) on a Special Issue of the Geneva Papers on Risk and Insurance on Insurance and Emerging Health Risks. His current research interests include health service innovations to improve the health of people with chronic kidney disease(CKD). Ongoing interests include the economics of disability and insurance, compensable injury compensation schemes, and the determinants of health. Luke enjoys and has considerable experience teaching economics and health economics at both the graduate and undergraduate levels. In 2014 he was awarded the School of Economics Distinguished Teaching Award for his teaching on UQ's Master of Health Economics Program. In July 2016 and July 2019 he also taught summer schools in Health Economics and the Economics of Insurance at The University of Lucerne, Switzerland. Over the past 10 years he has been a chief investigator on grants totalling more than $70m.
Most Relevant Publications (1+)

105 total publications

An economic evaluation of plasma production via erythroplasmapheresis and whole blood collection

Transfusion and Apheresis Science / Oct 01, 2002

Connelly, L. B., & Pink, A. (2002). An economic evaluation of plasma production via erythroplasmapheresis and whole blood collection. Transfusion and Apheresis Science, 27(2), 101–111. https://doi.org/10.1016/s1473-0502(02)00046-0

See Full Profile

Mohsen Fathzadeh

Research Scientist, Genomics, Stanford University
Most Relevant Research Expertise
Hematology
Other Research Expertise (16)
Genomic Medicine
Translational Genomics
Diabetes Prevention
Cardiometabolic Diseases
Single-Cell Genomics
And 11 more
About
## Scientist Genomics I have my major, MSc, and PhD degrees in biology, human, and medical genetics. I have hands-on experience in a variety of molecular biology and genetic techniques and have worked on NGS library preparation, scRNA-seq, and data analysis. As shown in my resume (I can also send my CV if needed), in addition to genomic experiments, I have worked on other omic profiling such as epigenome (DNA methylation), proteomics, and transcriptomics in a variety of samples including human cells and animal tissues. With more than 20 years of work experience, I have worked in hospital, academic, and biotech settings and proactively had to take a strategic thinking and problem-solving approach. Thus, I am adaptable to changing directions and methods, and eager to work in a dynamic, fast-paced research and product development environment. I also have multiple experiences managing multicenter and international collaborations and managing multiple priorities in a cross-functional team. I personally give fundamental value to diversity and building new connections and collaborations, and learning from diverse team members. Continuous learning and teamwork are my core values. There are other examples of my attention to detail, optimizing and troubleshooting techniques and experiments in molecular biology, genomics, and NGS panel design. As an example of my resilience, in a collaboration between CZ Biohub and the Stanford Pediatrics Department, I had to pilot a split-seq and combinatorial barcoding NGS method for newborn lung samples from library preparation up to scRNA-seq analysis. With a strong background in genomics and biology and expertise in the wet lab and data analysis, I could be a valuable asset to the Product Development teams where they need someone to lead and advance genomics research and NGS technology development, outreach, and shaping the future of genomics research, especially in clinical genetics and medical genomics. As I pursue a multidisciplinary collaboration in my scientific rationale, particularly, I am eager to extend my dedication to commercialization and envision the genomics product for financial gain and bringing value to the market. In summary, I have expertise and am eager to continue to design, conduct, and optimize new biological and genomics experiments and elucidate underlying mechanisms. I have more than 20 years of direct work experience in clinical research, both within hospital settings and in functional genomics labs. These roles required me to perform a variety of monitoring tasks depending on the context. This included monitoring lab and patient data, as well as monitoring various types of data such as clinical, molecular, and omics data, including genomics and proteomics. I have experience in developing IVD tests such as NGS panels and Polygenic Risk Scores (PRS) for genetic diseases.
Most Relevant Publications (1+)

30 total publications

Apolipoprotein E gene polymorphism and left ventricular function in Iranian patients with thalassemia major

Haematologica / Feb 01, 2007

Bazrgar, M., Karimi, M., Peiravian, F., & Fathzadeh, M. (2007). Apolipoprotein E gene polymorphism and left ventricular function in Iranian patients with thalassemia major. Haematologica, 92(2), 256–257. https://doi.org/10.3324/haematol.10708

See Full Profile

Example hematology projects

How can companies collaborate more effectively with researchers, experts, and thought leaders to make progress on hematology?

Development of Novel Hematology Diagnostic Tool

A company in the medical device industry can benefit from collaborating with a Hematology researcher to develop a novel diagnostic tool for blood disorders. The researcher's expertise in analyzing blood samples and identifying specific markers can contribute to the development of an accurate and efficient diagnostic device.

Drug Discovery for Hematological Cancers

A pharmaceutical company focused on oncology can collaborate with a Hematology researcher to discover new drugs for hematological cancers. The researcher's deep understanding of the molecular mechanisms involved in blood cancers can guide the development of targeted therapies.

Improving Blood Transfusion Practices

A healthcare organization can partner with a Hematology researcher to improve blood transfusion practices. The researcher's knowledge of blood compatibility, transfusion reactions, and storage techniques can help optimize transfusion protocols and ensure patient safety.

Development of Gene Therapies for Hemophilia

A biotechnology company can collaborate with a Hematology researcher to develop gene therapies for hemophilia. The researcher's expertise in gene editing and delivery systems can contribute to the development of innovative treatments for this genetic blood disorder.

Exploring Stem Cell Therapies for Blood Disorders

A regenerative medicine company can work with a Hematology researcher to explore the potential of stem cell therapies for blood disorders. The researcher's knowledge of hematopoietic stem cells and their differentiation can aid in developing novel therapeutic approaches.